JP2013506715A5 - - Google Patents

Download PDF

Info

Publication number
JP2013506715A5
JP2013506715A5 JP2012533248A JP2012533248A JP2013506715A5 JP 2013506715 A5 JP2013506715 A5 JP 2013506715A5 JP 2012533248 A JP2012533248 A JP 2012533248A JP 2012533248 A JP2012533248 A JP 2012533248A JP 2013506715 A5 JP2013506715 A5 JP 2013506715A5
Authority
JP
Japan
Prior art keywords
nitrogen
oxygen
membered
ring
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012533248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013506715A (ja
JP6016635B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/051517 external-priority patent/WO2011044157A1/en
Publication of JP2013506715A publication Critical patent/JP2013506715A/ja
Publication of JP2013506715A5 publication Critical patent/JP2013506715A5/ja
Application granted granted Critical
Publication of JP6016635B2 publication Critical patent/JP6016635B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012533248A 2009-10-06 2010-10-05 Ｐｄｋ１インヒビターとして有用な複素環式化合物 Expired - Fee Related JP6016635B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24909509P 2009-10-06 2009-10-06
US61/249,095 2009-10-06
PCT/US2010/051517 WO2011044157A1 (en) 2009-10-06 2010-10-05 Heterocyclic compounds useful as pdk1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016155272A Division JP2016188253A (ja) 2009-10-06 2016-08-08 Ｐｄｋ１インヒビターとして有用な複素環式化合物

Publications (3)

Publication Number Publication Date
JP2013506715A JP2013506715A (ja) 2013-02-28
JP2013506715A5 true JP2013506715A5 (https=) 2013-11-14
JP6016635B2 JP6016635B2 (ja) 2016-10-26

Family

ID=43857093

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012533248A Expired - Fee Related JP6016635B2 (ja) 2009-10-06 2010-10-05 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2016155272A Withdrawn JP2016188253A (ja) 2009-10-06 2016-08-08 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2018106041A Pending JP2018145196A (ja) 2009-10-06 2018-06-01 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2020149736A Withdrawn JP2020203925A (ja) 2009-10-06 2020-09-07 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2022177407A Pending JP2023002840A (ja) 2009-10-06 2022-11-04 Ｐｄｋ１インヒビターとして有用な複素環式化合物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016155272A Withdrawn JP2016188253A (ja) 2009-10-06 2016-08-08 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2018106041A Pending JP2018145196A (ja) 2009-10-06 2018-06-01 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2020149736A Withdrawn JP2020203925A (ja) 2009-10-06 2020-09-07 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2022177407A Pending JP2023002840A (ja) 2009-10-06 2022-11-04 Ｐｄｋ１インヒビターとして有用な複素環式化合物

Country Status (27)

Country Link
US (6) US9546165B2 (https=)
EP (3) EP3070077B1 (https=)
JP (5) JP6016635B2 (https=)
KR (3) KR20120087936A (https=)
CN (1) CN102665718B (https=)
AR (2) AR078540A1 (https=)
AU (3) AU2010303567B2 (https=)
BR (1) BR112012007747B8 (https=)
CA (1) CA2776690C (https=)
CY (1) CY1118143T1 (https=)
DK (2) DK2485731T3 (https=)
ES (2) ES2586856T3 (https=)
HR (1) HRP20160967T1 (https=)
HU (2) HUE028082T2 (https=)
IL (4) IL266563B (https=)
IN (1) IN2012DN03883A (https=)
LT (1) LT2485731T (https=)
MX (2) MX389288B (https=)
PH (1) PH12012500674A1 (https=)
PL (1) PL2485731T4 (https=)
PT (1) PT2485731T (https=)
RS (1) RS55101B1 (https=)
RU (2) RU2615130C2 (https=)
SI (1) SI2485731T1 (https=)
SM (1) SMT201600275B (https=)
TW (1) TWI525093B (https=)
WO (1) WO2011044157A1 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
IL266563B (en) 2009-10-06 2022-09-01 Millennium Pharm Inc Heterocyclic compounds useful as pdk1 inhibitors
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
US9062008B2 (en) * 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9321735B2 (en) 2010-07-20 2016-04-26 Vestaron Corporation Insecticidal triazines and pyrimidines
NZ607527A (en) 2010-09-16 2015-04-24 Hutchison Medipharma Ltd Fused heteroaryls and their uses
US8791112B2 (en) 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN106496173A (zh) 2011-09-30 2017-03-15 沃泰克斯药物股份有限公司 用于制备可用作atr激酶抑制剂的化合物的方法
CN108685922A (zh) 2011-09-30 2018-10-23 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
CN103159741B (zh) * 2011-12-19 2016-08-24 天津市国际生物医药联合研究院 一类酪氨酸激酶抑制剂的制备和用途
CN108478577A (zh) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
CN102627632B (zh) * 2012-04-16 2014-06-18 中国科学院广州生物医药与健康研究院 一种胺基喹唑啉衍生物及其制备方法和用途
NZ631258A (en) 2012-04-25 2016-11-25 Takeda Pharmaceuticals Co Nitrogenated heterocyclic compound
CA2871651A1 (en) * 2012-05-08 2013-11-14 Anvyl Llc Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
WO2014010732A1 (ja) 2012-07-13 2014-01-16 武田薬品工業株式会社 複素環化合物
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
WO2014192936A1 (ja) * 2013-05-31 2014-12-04 日産化学工業株式会社 複素環アミド化合物
JP6427491B2 (ja) 2013-07-03 2018-11-21 武田薬品工業株式会社 複素環化合物
EP3018123B1 (en) 2013-07-03 2023-05-10 Takeda Pharmaceutical Company Limited Amide compound
JPWO2015012328A1 (ja) 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
SG10201804471PA (en) 2013-10-18 2018-07-30 Celgene Quanticel Research Inc Bromodomain inhibitors
WO2015073804A2 (en) * 2013-11-15 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of blocking transmission of malarial parasite
WO2015077572A1 (en) 2013-11-22 2015-05-28 CL BioSciences LLC Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
CN104130256B (zh) * 2014-08-01 2016-08-24 上海毕得医药科技有限公司 一种吡啶并[3,4-d]嘧啶-4（3H）-酮衍生物的制备方法
ES2807785T3 (es) * 2014-10-22 2021-02-24 Bristol Myers Squibb Co Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
KR102562866B1 (ko) 2014-11-14 2023-08-04 네르비아노 메디칼 사이언시스 에스.알.엘. 단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
WO2017015152A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
CN105130980B (zh) * 2015-09-09 2018-05-22 沈阳药科大学 N-3-苯并咪唑噻唑胺类衍生物及其制备方法与应用
RU2722149C1 (ru) * 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
KR101753652B1 (ko) * 2015-10-21 2017-07-05 한국화학연구원 N-아릴-1h-피라졸로피리딘-3-아민 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 melk 관련 질환의 예방 또는 치료용 약학적 조성물
KR101753654B1 (ko) 2015-10-21 2017-07-05 한국화학연구원 3-(4-(피페라진-1-일)벤즈아미도)-1h-피라졸로피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 melk 관련 질환의 예방 또는 치료용 약학적 조성물
AU2016342352B2 (en) * 2015-10-23 2022-06-02 Sunesis Pharmaceuticals, Inc. Heterocyclic PDK1 inhibitors for use to treat cancer
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
KR102483020B1 (ko) 2016-03-28 2023-01-04 인사이트 코포레이션 Tam 저해제로서의 피롤로트리아진 화합물
EP3445750A4 (en) 2016-04-18 2019-11-27 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
TW201811795A (zh) 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基－吡咯并嘧啶酮化合物及其用途
JP7091336B2 (ja) 2016-12-22 2022-06-27 グローバル ブラッド セラピューティクス インコーポレイテッド ヒストンメチルトランスフェラーゼ阻害剤
CN110382554B (zh) * 2017-03-10 2022-03-22 大塚化学株式会社 反应产物及橡胶组合物
WO2018226998A1 (en) * 2017-06-09 2018-12-13 Global Blood Therapeutics, Inc. Azaindole compounds as histone methyltransferase inhibitors
US20190175589A1 (en) * 2017-11-09 2019-06-13 Sunesis Pharmaceuticals, Inc. Pharmaceutical formulations, processes for preparation, and methods of use
SG11202007035YA (en) 2018-01-26 2020-08-28 Bristol Myers Squibb Co Aminopyrrolotriazines as kinase inhibitors
CN109087534A (zh) * 2018-10-09 2018-12-25 王业宝 一种基于车辆行驶轨迹的交通冲突检测方法
US11780857B2 (en) * 2019-04-17 2023-10-10 EWHA University—Industry Collaboration Foundation Probe compounds for amino alcohols, and simultaneous fluorescence and circular dichroism analysis method
CN110066221B (zh) * 2019-05-16 2022-03-08 海门瑞一医药科技有限公司 一种环丙基甲胺的制备方法
WO2021064141A1 (en) * 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
KR102877132B1 (ko) * 2019-11-25 2025-10-27 주식회사 대웅제약 신규한 트리아졸로피리딘 유도체 및 이를 포함하는 약학 조성물
US20240116962A1 (en) * 2020-12-31 2024-04-11 Tsinghua University Pyridine-2-amine derivative and pharmaceutical composition and use thereof
AR127972A1 (es) * 2021-12-17 2024-03-13 Pi Industries Ltd Novedosos compuestos de piridina carboxamida bicíclica sustituida fusionada para combatir hongos fitopatogénicos
CN118974044A (zh) * 2021-12-24 2024-11-15 赛洛私人有限公司 化合物
WO2024040242A1 (en) 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Combinations of pdk1 inhibitors and kinase inhibitors
WO2024040241A1 (en) 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Pharmaceutical formulations, processes for preparation, and methods of use
EP4698169A2 (en) * 2023-04-21 2026-02-25 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
CN117603068A (zh) * 2023-08-01 2024-02-27 常州寅盛药业有限公司 一种氨甲环酸的制备方法
WO2025076290A1 (en) * 2023-10-05 2025-04-10 Purdue Research Foundation 5-6-5/6-bisaryl compounds as flt3 inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3175980A (en) * 1958-05-23 1965-03-30 Geigy Ag J R Compositions of matter of improved appearance in daylight, containing a 3.5-diaminopyrazine-2.6-dicarboxylic acid derivative
DE2143730A1 (de) * 1971-09-01 1973-03-08 Byk Gulden Lomberg Chem Fab Substituierte pyridine, verfahren zu deren herstellung und sie enthaltende arzneimittel
PL114780B1 (en) * 1978-03-10 1981-02-28 Inst Przemyslu Farmaceutic Process for preparing novel alkylamides of 2-anilinonicotinic acids
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JP3258776B2 (ja) * 1993-06-30 2002-02-18 中外製薬株式会社 Ｎ−スチリルフェニルアミノ安息香酸誘導体
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
CA2358095A1 (en) * 1998-12-23 2000-07-06 Eli Lilly And Company Heteroroaromatic amides as inhibitor of factor xa
JP2004522689A (ja) * 1998-12-23 2004-07-29 イーライ・リリー・アンド・カンパニー 抗血栓アミド類
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
JP2006503094A (ja) * 2002-10-16 2006-01-26 スミスクライン ビーチャム コーポレーション 化合物
WO2004056806A1 (en) * 2002-12-19 2004-07-08 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
EP1646628A1 (en) 2003-07-08 2006-04-19 Novartis AG Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
WO2005039564A1 (en) 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
RU2006117635A (ru) * 2003-10-24 2007-12-10 Шеринг Акциенгезельшафт (De) Производные индолинона и их применение для лечения патологических состояний, таких как злокачественное новообразование
AR049418A1 (es) * 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
SE0401345D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
EP1655297A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
CA2610509A1 (en) 2005-06-03 2006-12-14 Bayer Healthcare Ag 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
JP5523829B2 (ja) * 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド 複合薬剤
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
WO2008016643A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008079294A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
EP2139882B1 (en) * 2007-03-23 2013-12-25 Amgen Inc. 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
JP5478488B2 (ja) 2007-06-20 2014-04-23 メルク・シャープ・アンド・ドーム・コーポレーション Ｊａｎｕｓキナーゼの阻害剤
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
JP2012529512A (ja) * 2009-06-08 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
IL266563B (en) 2009-10-06 2022-09-01 Millennium Pharm Inc Heterocyclic compounds useful as pdk1 inhibitors

Similar Documents

Publication Publication Date Title
JP2013506715A5 (https=)
RU2012118667A (ru) Гетероциклические соединения, используемые в качестве ингибиторов pdk1
Mokale et al. Synthesis and anti-inflammatory activity of some 3-(4, 6-disubtituted-2-thioxo-1, 2, 3, 4-tetrahydropyrimidin-5-yl) propanoic acid derivatives
AU2015355839B2 (en) Heterocyclic derivatives and use thereof
JP2015532295A5 (https=)
JP2013503905A5 (https=)
JP2016509047A5 (https=)
JP2014503567A5 (https=)
BR112013026137B1 (pt) pirimidinil-pirróis substituídos ativos como inibidores da quinase
RU2010147404A (ru) Замещенные дигидропиразолоны в качестве ингибиторов hif-пролил-4-гидроксилазы
US8822732B2 (en) 1,5-diphenyl-penta-1,4-dien-3-one compounds
JP2009530424A5 (https=)
KR20130099064A (ko) (아자)인돌리진 유도체 및 그 의약용도
JP2012504608A5 (https=)
JP2024515062A (ja) 重水素化ｄｈｏｄｈ阻害剤
JP2016525104A5 (https=)
JP2024096821A (ja) 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸
KR101648377B1 (ko) 축합환 유도체 및 그 의약용도
JP2025500176A (ja) カルボン酸バイオアイソスタを含むｄｈｏｄｈ阻害剤
JP2010510216A5 (https=)
JPWO2005080322A1 (ja) フルオレン誘導体
AU2012236275B2 (en) Derivatives of sulindac, use thereof and preparation thereof
JP2018538244A5 (https=)
DK168861B1 (da) 4-methyl-5-(2-(4-phenyl-1-piperazinyl)ethyl)thiazolderivater og fremgangsmåde til fremstilling deraf, farmaceutiske midler indeholdende thiazolderivaterne og fremgangsmåde til fremstilling deraf og anvendelse af derivaterne til fremstilling af lægemidler
JP5302214B2 (ja) Ｔｒｐｖ１受容体拮抗薬としてのｏ−置換ジベンジル尿素誘導体